Axxam GmbH is the German subsidiary of Axxam S.p.A. created on January 1, 2022 from the merger of Hit Discovery Constance GmbH and IMAX Discovery GmbH. Axxam GmbH is structured into two business units, namely Discovery Services Constance (“DSC”) and IMAX Discovery, deriving respectively from the two original companies.
Under the new name we will continue to offer our competences, resources and experience to our customers and partners in order to support their research projects and face together the new challenges with a joint and integrated approach.
About the Business Unit Discovery Services Constance deriving from Hit Discovery Constance GmbH
In 2014 Hit Discovery Constance GmbH (“HDC”) was founded as a joint venture company between Axxam S.p.A. (Milan, Italy), Centre for Drug Design and Discovery of KU Leuven (Leuven, Belgium) and Lead Discovery Center GmbH (Dortmund, Germany). In 2021 Axxam S.p.A. announced the entire acquisition of the share capital of Hit Discovery Constance GmbH which in the meanwhile became a qualified provider of early-stage drug discovery services for the life sciences industry, staffed and operated by experienced scientists who have run drug discovery and HTS projects in major pharmaceutical, biotechnology and academic institutions in Germany and around the world.
The high-quality services include high-throughput screening (1536 and 384 well formats) and radiometric screening (SPA, flash-plate).
About the Business Unit IMAX Discovery deriving from IMAX Discovery GmbH
IMAX Discovery GmbH is a research company incorporated in 2011 as an equity joint venture between IMD Natural Solutions GmbH (INS), a specialist in the field of natural products, and Axxam S.p.A., a leading company in discovery research.
Since its foundation IMAX Discovery has been involved in numerous successful R&D projects performed together with renowned companies in the food & beverage industry as well as flavor houses. Thanks to the long collaboration history, IMAX Discovery has gained an excellent reputation as innovator for new taste modulating ingredients and is trusted by various leading companies in the field.
In early 2018 IMAX Discovery became a 100% subsidiary of Axxam S.p.A., with the consequent acquisition of the natural product libraries of INS. Concurrently, Axxam transferred its service business within the fragrance field into IMAX Discovery.
IMAX Discovery offers its clients and partners integrated solutions across the entire discovery process starting from flavor, fragrance and cosmetic target identification and validation up to the selection and development of new bioactive compounds by providing services, tools and integrated solutions tailored to the specific needs of its clients and partners.
Other participated companies
Axxam S.p.A. is also a shareholder of the following companies:
Acousia Therapeutics GmbH (“Acousia”) is a privately held biotech company based in Tübingen, Germany, dedicated to the identification of small molecules for innovative treatments of hearing loss. The new therapeutic approach will replace lost sensory hair cells, the key cells for hearing in the inner ear, by cellular regeneration originating from supporting cells. Axxam has transferred certain therapeutic assets to the R&D programs of Acousia. These programs will be further progressed by Acousia to generate clinical candidates to be developed subsequently to demonstrate clinical proof of concept.
Libra Therapeutics, Inc. (“Libra”) is an early-stage drug discovery company founded by Axxam and based in San Diego (US). Libra is focused on the development of innovative small-molecule therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases with a huge unmet medical need. Libra will take advantage of the collaboration with Axxam to further optimize the molecules identified thanks to highly innovative assays on genetically validated targets, with the goal to bring first-in-class therapies to the clinic. In its ambitious mission, Libra will also have the support of an excellent Scientific Advisory Board of KOLs, covering all the competences from understanding the molecular mechanisms of the pathology to clinical trials.
Muna Therapeutics Aps (“Muna”) is a private biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe. Muna focuses its groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases. Its name reflects this focus: Muna means ‘to remember’ in Old Norse.
Rewind Therapeutics NV (“Rewind”) is a pre-clinical drug discovery company based in Leuven, Belgium, dedicated to the development of novel small molecule re-myelinating therapies for patients with multiple sclerosis and other de-myelinating diseases. In close collaboration with the founders (Axxam and the Centre for Drug Design and Discovery – CD3, Leuven, Belgium) and a world-class academic network, Rewind aspires to advance innovative first-in-class therapies for myelin-related diseases into fast track clinical application. These programs will be further progressed by Rewind to further expand its pipeline of novel drug candidates targeting myelin disorders.